Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
Authors' conclusion
The prevalence of SGLT2i and GLP-1RA use varied by geography, probably reflecting a combination of system- and prescriber-level factors. Socio-economic variation in GLP-1RA use was overshadowed by localized patterns of prescribing. Continued monitoring of variation can help shape interventions to optimize use among people who would benefit the most.
Study context
- Population
- New South Wales residents aged ≥40 years who dispensed metformin in 2020 (proxy for T2D)
- Participants
- 367,829 residents
- Outcome
- Prevalence of SGLT2i and GLP-1 RA use among people with T2D and among people using concomitant T2D therapy, by small-level geography, age group, remoteness and socio-economic status
- Follow-up
- 2020
Methodological detailspopulation-based, small-area geographic analysis
- Population-based
- Small-area geographic analysis
Main finding
As reported in the abstract
- SGLT2i use, people with T2D aged 40-64
- 29.7%
- GLP-1 RA use, people with T2D aged 40-64
- 8.3%
- SGLT2i use among people using concomitant T2D therapy
- 55.4%
- GLP-1 RA use among people using concomitant T2D therapy
- 15.4%
- Localized areas of high GLP-1 RA use
- 2.5 times the median
Observational data: associations, not effects.
Further findings
SGLT2i and GLP-1 RA use by age group
- Prevalence lower in older age groups than at 40-64 years, with similar patterns of geographic variation
Original publication
Geographic variation in sodium‐glucose cotransporter 2 inhibitor and glucagon‐like peptide‐1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia. Diabetes Obes Metab. Published 15 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →